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Abstract 
Background 
The available evidence from randomised controlled trials suggests that vitamin B12 
supplementation does not improve neurologic function in older people with marginal but 
not deficient Vitamin B12 status.  This secondary analysis used data from the Older People 
and Enhanced Neurological function (OPEN) randomised controlled trial to assess whether 
baseline vitamin B12 status or change in vitamin B12 status over 12 months altered the 
effectiveness of dietary vitamin B12 supplementation on neurologic function in 
asymptomatic older people with depleted vitamin B12 status at study entry. 
Methods 
Vitamin B12 status was measured as serum concentrations of vitamin B12, 
holotranscobalamin, homocysteine and via a composite indicator (cB12).  Neurological 
function outcomes included eleven electrophysiological measures of sensory and motor 
components of peripheral and central nerve function.  Linear regression analyses were 
restricted to participants randomised into the intervention arm of the OPEN trial (n=91). 
Results 
Analyses revealed an inconsistent pattern of moderate associations between some 
measures of baseline vitamin B12 status and some neurological responses to 
supplementation.  The directions of effect varied and heterogeneity in effect across 
outcomes could not be explained according to type of neurologic outcome. There was no 
evidence of differences in the neurological response to vitamin B12 supplementation 
according to change from baseline over 12 months in any indicator of B12 status. 
Conclusions 
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This secondary analysis of high quality data from the OPEN trial provides no evidence that 
baseline (or change from baseline) vitamin B12 status modifies the effect of vitamin B12 
supplementation on peripheral or central nerve conduction among older people with 
marginal vitamin B12 status.  There is currently insufficient evidence of efficacy for 
neurological function to support population-wide recommendations for vitamin B12 
supplementation in healthy asymptomatic older people with marginal vitamin B12 status. 
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Introduction 
Ageing is associated with a decline in vitamin B12 status, and prevalence of vitamin B12 
deficiency increases with age1.  As dietary intakes are usually adequate in healthy 
populations2, the age-related decline in vitamin B12 status is usually attributed to atrophic 
gastritis which reduces absorption of vitamin B123.  Adequate vitamin B12 is necessary for 
optimal neurologic function.  Symptoms of peripheral neuropathy associated with vitamin 
B12 deficiency commonly include symmetric paresthesias, numbness or gait problems, 
impaired position and cutaneous sensation, impaired vibration sense and weakness4, 5.  
 
In the light of the high prevalence of preclinical deficiency, routine vitamin B12 
supplementation has been proposed in older people6 7.  Indeed, US adults aged >50 years 
are advised to meet their recommended daily allowance of 2.4 µg vitamin B12 per day 
mainly by consuming either food fortified with vitamin B12 or a vitamin B12-containing 
supplement7.  Yet surprisingly few studies8-12 are available to help understand whether 
vitamin B12 supplementation improves neurological function in older people and overall, 
these studies (while heterogeneous in size, effect and quality) do not suggest that there is 
strong evidence that vitamin B12 supplementation improves neurologic function in older 
people in the absence of frank vitamin B12 deficiency. 
 
It is however possible that improvement in neurologic function resulting from vitamin B12 
supplementation may be apparent only in non-deficient people with the most marginal 
vitamin B12 status.   For example, while primary analyses from the randomised controlled 
trial (RCT) by Hvas et al.9 showed no difference in neurologic outcomes between 
intervention (1mg cyanocobalamin administered intramuscularly weekly for four weeks) and 
5 
 
control arms, there was evidence of effectiveness of treatment in individuals with the 
lowest vitamin B12 status at study entry.  There is similar evidence to support greater 
benefits of vitamin B12 supplementation in people with the lowest vitamin B12 status from 
studies on cognitive outcomes.  The VITACOG RCT reported that administering high doses of 
folic acid, vitamin B6 and vitamin B12 over two years on measures of brain atrophy and 
several other cognitive outcomes was more beneficial in individuals with the highest 
baseline plasma tHcy levels 13, 14. 
 
The Older People and Enhanced Neurological function (OPEN) RCT provides an opportunity 
to explore further, in a high quality dataset, whether improvement in neurologic function 
from vitamin B12 supplementation is limited to people with the lowest baseline vitamin B12 
status.  The OPEN study was a double-blind placebo-controlled RCT investigating the effects 
of 1mg vitamin B12 oral supplementation for 12 months on electrophysiological indices of 
neurologic function in older people aged 75+ years with marginal vitamin B12 status.  The 
primary results from the trial demonstrated no effect of vitamin B12 supplementation on 
any measure of nerve function11.  This secondary analysis explores whether differences in 
baseline vitamin B12 status or change in vitamin B12 status over 12 months of intervention 
alters the effectiveness of vitamin B12 supplementation on electrophysiological indices of 
neurologic function in asymptomatic older people with marginal vitamin B12 status at study 
entry. 
 
Methods 
This study is a secondary analysis of data from the OPEN study, the protocol of which has 
been published15 (www.isrctn.com; ISRCTN54195799).  Screening for participation in the 
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OPEN study took place between November 2008 and February 2010.  Participants were 
aged 75+ years and recruited from 7 general practices in South East England. Individuals 
with dementia, epilepsy, alcohol addiction, diabetes, pacemakers or other implanted 
metallic devices, residents of nursing homes, or a previous diagnosis of pernicious anaemia 
were excluded. Potential participants with significant cognitive impairment or who reported 
current consumption of vitamin B12 supplements or who had received a vitamin B12 
injection in the previous 6 months were excluded. Individuals with moderate vitamin B12 
deficiency [serum vitamin B12 concentrations ≥107 and <210pmol/L (using a Beckman 
Coulter assay)] who did not have anaemia (haemoglobin concentrations ≥110g/L for women 
and ≥120g/L for men) were eligible to join the study.  
 
Participants, who provided informed consent, were enrolled in the trial and randomised to 
treatment (n=99) or placebo arms (n=102).  Allocation to treatment was balanced by age 
and sex, and all participants and investigators were blind to treatment allocation.  Allocated 
treatment consisted of a single tablet containing 1mg vitamin B12 (cyanocobalamin) daily 
for 12 months.  91 participants in each arm of the trial provided follow-up data on the OPEN 
trial primary outcome: posterior tibial compound muscle action potential (CMAP) 
amplitude.  The OPEN study was designed to achieve 90% power to detect a ≥28% 
difference in the primary outcome (with 5% significance) between arms of the trial. 
 
At baseline and after 12 months follow-up, participants provided a blood sample and 
undertook a series of neurophysiological function tests.  Blood samples were analysed for 
serum concentrations of vitamin B12 (using a microbiologic assay); holotranscobalamin 
(holoTC; Axis-Shield radioimmunoassay; Axis-Shield plc) and total homocysteine (tHcy; 
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Abbott IMx analyzer; Abbott Laboratories) in a single laboratory in Trinity College Dublin.  
The microbiologic assay for vitamin B12 (used at study entry) typically provides estimates of 
serum vitamin B12 concentration that are ~25% higher than those produced by the 
Beckman Coulter method (used at initial screening).  Median (and interquartile range) 
values for serum vitamin B12 (estimated using the microbiologic assay by the same 
laboratory in Trinity College Dublin) among older people in Ireland have recently been 
published as 277 (216-369) pmol/L16.  88% of OPEN study participants had vitamin B12 
status below the median value for the microbiologic assay reference standard (derived from 
a random sample of 470 from nationally representative adults in the Irish National Adult 
Nutrition Survey) (personal communication Dr Anne Molloy, 2013), indicating that OPEN 
study participants had marginal vitamin B12 status at study entry. 
 
A single expert neurophysiologist (KM) conducted a battery of peripheral nerve conduction 
tests and central motor conduction tests at baseline and follow-up.  Standard techniques 
were used involving surface electrodes.  Skin temperature of the dorsum of the foot and 
hand was measured to allow for appropriate adjustments in the analyses because nerve 
conduction in peripheral nerves is sensitive to temperature of the limbs17.  Posterior tibial 
CMAP amplitude evoked by distal stimulation was the primary trial outcome.  The seven 
secondary peripheral nerve outcomes were common peroneal CMAP amplitude (also 
evoked by distal stimulation); posterior tibial and common peroneal conduction velocities 
measured by recording from the adductor hallucis (AH) and extensor digitorum brevis 
muscles respectively; and sensory action potential (SAP) amplitude (maximum deviation of 
the electrical response) and conduction velocity measured in the sural and superficial 
peroneal nerves.  Together these outcomes represent each component of peripheral nerve 
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function: posterior tibial and common peroneal CMAP reflects the number of motor axons 
that can be accessed by an electrical stimulus which in turn reflects muscle strength18, 19; 
sural and superficial peroneal SAP amplitudes are indices of nerve fibre number; and 
sensory (sural and superficial peroneal nerve) or motor (posterior tibial and common 
peroneal) conduction velocity is an indicator of myelination20.  All nerve conduction 
outcomes were measured on the right side of the body. 
 
Central motor conduction tests were measured using transcranial magnetic stimulation, 
which painlessly and noninvasively excites the motor cortex21.  Further secondary outcomes 
were mean abductor digiti motor (ADM) motor evoked potential (MEP) amplitude, and ADM 
and AH central motor conduction time (CMCT).   With the right ADM muscle partially 
activated voluntarily, stimuli were delivered to evoke MEPs, and mean amplitudes were 
measured.  Similarly, the leg area of motor cortex was excited to measure MEPs evoked in 
the AH muscle.  ADM and AH CMCT were calculated by subtracting the time to response in 
each muscle from an estimate of the peripheral nerve conduction time.  
 
Vitamin B12 and holoTC were used as measures of vitamin B12 status.  In addition, cB12 
was used as a composite indicator of vitamin B12 status combining vitamin B12, holoTC and 
tHcy22.  Although tHcy alone does not have good specificity as an indicator of vitamin B12 
status, it is also included as an indicator of vitamin B12 in this study for exploratory 
purposes. 
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Statistical analysis 
Secondary analyses were performed to explore whether baseline or change in vitamin B12 
status altered the impact of dietary vitamin B12 supplementation on neurologic function. 
Analyses were restricted to the intervention arm (n=91), because the placebo arm did not 
receive any vitamin B12 supplementation and accordingly, change in vitamin B12 status was 
negligible11, and minor changes in nerve conduction were assumed to be due to variability 
in repeated measures.  Analyses were exploratory in nature and aimed to identify consistent 
patterns in findings rather than applying stringent p-values to test for statistical significance. 
 
The effects of supplementation on vitamin B12 status according to baseline status were 
explored by baseline quartiles of vitamin B12, holoTC, tHcy and cB12 as indicators of vitamin 
B12 status.  Linear regression models were used to test for associations between baseline 
and change in vitamin B12 status (measured by vitamin B12, holoTC, tHcy and cB12) and 
neurologic response to vitamin B12 supplementation.  Eleven nerve conduction outcomes 
were used, consistent with the outcomes used in the primary analyses from the OPEN 
study11.  For each nerve conduction outcome, linear regression models tested for 
associations between baseline vitamin B12 status and change in the outcome (in response 
to supplementation), adjusted for the corresponding baseline measure of nerve conduction, 
age, sex and change in skin temperature.  Similarly, linear regression models tested for 
associations between change in vitamin B12 status and change in the outcome (in response 
to supplementation) for the same nerve conduction outcomes; adjustments included 
baseline measures of vitamin B12 in addition to those listed above.  All linear regression 
models were boot-strapped to allow for non-normal distributions of exposures and 
outcomes. Results are presented as mean change in outcome with bias-corrected 95% 
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confidence intervals. Because the analyses involved multiple comparisons, p-values have 
been interpreted with caution.  Statistical analyses were conducted using STATA (version 14 
StataCorp, Texas USA). 
 
Ethics 
The OPEN study was reviewed and approved by the National Research Ethics Committee 
(08/H0305/18) and the London School of Hygiene & Tropical Medicine Ethics Committee 
(LSHTM) (no. 5298).  The secondary analyses presented here were approved by the LSHTM 
Ethics Committee (no. 7176). 
 
Results 
Participants included in the current analysis had a mean age of 79.9 years and 46.5% were 
male.  Comparing baseline with 12 months, oral supplementation was effective in increasing 
vitamin B12 status: vitamin B12, holoTC and cB12 increased (mean change 409.6 pmol/L, 
184.3 pmol/L and 1.5 respectively) and tHcy (mean change -2.8 µmol/L) decreased at 12 
month follow-up (Table 1).  Levels of vitamin B12 and cB12 at follow-up were constant 
across quartiles of baseline status (vitamin B12: F test p=0.44; cB12: F test p=0.21), 
suggesting a plateau effect (Figure 1).  In contrast, the effect of vitamin B12 
supplementation on tHcy and holoTC differed across baseline quartiles (tHcy: test for trend 
p<0.001; holoTC: test for trend p=0.01). 
 
Linear regression models found no evidence of a difference in impact of vitamin B12 
supplementation on the primary trial outcome (posterior tibial CMAP amplitude) (Table 2).  
For the other nerve function outcomes, effect sizes were generally small and patterns of 
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effect inconsistent.  There was evidence of an association of baseline vitamin B12 status 
with common peroneal CMAP amplitude, with higher baseline vitamin B12 being associated 
with a smaller change in common peroneal CMAP amplitude in response to 
supplementation [β=-0.01 (-0.01 - -0.00), p=0.02]; (p>0.05 for all other measures of vitamin 
B12 status). 
 
There was evidence of inverse associations of baseline vitamin B12 and cB12 with change in 
tibial motor conduction velocity; participants with the lowest baseline status tended to have 
a greater change in motor conduction velocity in response to supplementation over 12 
months.  In contrast, weak associations were detected between baseline holoTC and cB12 
and change in common peroneal motor conduction velocity in response to supplementation 
that suggest a greater change in motor conduction velocity with a higher baseline status.  
There is also evidence of a positive association of baseline vitamin B12 status with and a 
greater change in sensory sural conduction velocity in response to supplementation [β=0.02 
(0.00 – 0.03), p=0.05]; (p>0.05 for all other measures of vitamin B12 status). 
 
In measure of central nerve conduction, vitamin B12 supplementation improved (i.e. 
decreases) AH CMCT in participants with lower baseline cB12 status [β=2.19 (0.10 – 4.04), 
p=0.03].  Results for change in ADM CMCT were consistent in direction of effect but smaller 
in magnitude and not statistically significant [β=0.53 (-0.75 – 1.43), p=0.31].  In contrast, 
results for mean ADM MEP amplitude suggest that a greater response was observed in 
participants with higher baseline vitamin B12 status (as measured by tHcy and cB12). 
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Linear regression analyses show that neurologic response to vitamin B12 supplementation 
did not differ by change in vitamin B12 status (Table 3).  Null results are consistent across 
each measure of vitamin B12 status and all nerve conduction outcomes. 
 
Discussion 
Key findings 
The secondary analyses presented here used high quality data from the OPEN RCT to 
explore the relevance of baseline (or change from baseline) vitamin B12 status on the 
effectiveness of vitamin B12 supplementation for neurological function in older people with 
marginal vitamin B12 status.  The analysis did not identify an impact of baseline (or change 
from baseline) vitamin B12 status on the effect of vitamin B12 supplementation on the 
OPEN trial primary outcome (tibial compound muscle action potential amplitude).  When 
considering secondary neurological outcomes, analyses using some indicators of vitamin 
B12 status (but not others) revealed suggestive evidence of associations between baseline 
vitamin B12 status and some peripheral and central neurologic responses to 
supplementation.  However, directions of effect were inconsistent: an equal number of 
analyses showed suggestive evidence of greater neurologic improvement in response to 
supplementation in participants with higher baseline vitamin B12 status as there were 
analyses showing suggestive evidence of greater neurologic improvement in response to 
supplementation in participants with lower baseline vitamin B12 status.  Heterogeneity in 
findings across neurologic outcomes could not be explained by the aspect of neurologic 
function each outcomes measures: there were no differences in findings in peripheral 
versus central nerve conduction; motor versus sensory peripheral nerve conduction; or 
conduction velocities versus CMAP or SAP amplitudes.  Taken together, this secondary 
13 
 
analysis of OPEN trial data suggests that there is no evidence of differences in the effect of 
vitamin B12 supplementation on measures of nerve conduction based on baseline vitamin 
B12 status (vitamin B12, holoTC, tHcy or cB12).  This analysis also finds no evidence of 
difference in neurologic response to vitamin B12 supplementation according to any 
indicator of change in vitamin B12 status. 
 
Comparison with other studies 
Whilst previous reports9 suggested that individuals with the lowest vitamin B12 status might 
benefit most from an intramuscular vitamin B12 intervention in terms of neurological 
symptoms, results from this study indicate that this does not extend to benefits of an oral 
vitamin B12 intervention or improvements in nerve conduction.  This study also extends the 
primary findings of the OPEN RCT11 by exploring whether the null findings of the 
intervention might be attributed to the relatively replete vitamin B12 status of participants.  
As the secondary analyses found no consistent evidence of a greater benefit of vitamin B12 
supplementation in terms of neurologic function in those with the lowest vitamin B12 
status, it remains unlikely that the OPEN trial intervention would have been effective if 
participants had poorer vitamin B12 status at baseline alongside absence of neurologic or 
haematological symptoms of deficiency. 
 
Strengths and weaknesses 
The use of several measures of vitamin B12 status and measurement of neurologic function 
by nerve conduction are strengths of the study.  In particular, holoTC measures the active 
fraction of vitamin B12 and has been proposed as appropriate to use in the subclinical 
situation23, 24.  The use of cB12 has the advantage of combining biomarkers of circulating 
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vitamin B12 and a functional biomarker of vitamin B12 status22.  Poor renal function can be 
a cause of elevated tHcy6 and is also reported to be associated with cB1225 but was not 
measured in the OPEN study.  Nerve conduction tests use state-of-the-art methods and are 
objective measures.  All baseline and follow-up testing was conducted by a single 
neurophysiologist thereby eliminating inter-observer variability. 
 
It is recognised that this secondary analysis is limited in statistical power.  It is possible that 
trends would have been more easily detected in a larger study.  It is also possible that the 
statistically significant associations detected in this study were identified by chance as a 
result of multiple comparisons across several outcomes.  Furthermore, it remains possible 
that the duration of the vitamin B12 supplementation was too short and that benefits of 
supplementation only become evident after several years of treatment. 
 
Policy relevance and research needs 
This secondary analysis of the OPEN trial does not provide evidence to suggest that oral 
supplementation with vitamin B12 has beneficial effects on neurological function in 
individuals with marginal vitamin B12 status.  While prevention of vitamin B12 deficiency 
remains important, especially in older people, the available evidence does not support 
population-wide screening for moderate vitamin B12 deficiency in the absence of anaemia 
or neurological symptoms, nor population-wide recommendations for vitamin B12 
supplementation in healthy asymptomatic older people.  Treatment for neurological 
impairment attributed to vitamin B12 deficiency should be managed as appropriate by 
clinicians, rather than handled at the population level. 
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Table 1: Mean and standard deviation (SD) values by quartile of serum vitamin B121, holotranscobalamin (holoTC)2, homocysteine (tHcy)3 and a composite indicator 
(cB12) in the study population (n=91) of older people in the intervention arm of the OPEN study at baseline (0 months) and follow-up (12 months) 
 Baseline vitamin B12 
(pmol/L) 
Follow up vitamin B12 
(pmol/L) 
Baseline holoTC 
(pmol/L) 
Follow up holoTC 
(pmol/L) 
Baseline tHcy 
(µmol/L) 
Follow up tHcy 
(µmol/L) 
Baseline cB12 Follow up cB12 
Baseline 
quartile 
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
Q1 19 167.2 (18.8) 17 638.9 (221.6) 21 31.1 (5.8) 17 185.1 (83.8) 18 12.6 (0.9) 16 11.3 (1.0) 18 -0.7 (0.2) 15 1.1 (0.4) 
Q2 23 211.5 (8.8) 21 614.5 (244.5) 16 43.3 (2.0) 14 187.4 (93.6) 23 14.9 (0.7) 21 12.0 (1.4 ) 19 -0.3 (0.1) 17 1.3 (0.4) 
Q3 20 251.6 (13.6) 20 613.6 (99.3) 17 57.7 (5.3) 17 254.1 (152.5) 21 17.6 (1.0) 19 14.8 (2.1) 22 -0.1 (0.1) 21 1.2 (0.5) 
Q4 19 302.2 (26.4) 16 711.8 (203.8) 24 79.8 (14.8) 23 302.2 (221.3) 18 23.5 (4.6) 17 19.1 (5.5) 19 0.2 (0.2) 18 1.4 (0.5) 
 
1Microbiologic assay 
2Axis-Shield radioimmunoassay 
3Abbott IMx analyzer; Abbott Laboratories 
 
  
19 
 
Table 2: Linear regression analyses to assess relationship between baseline vitamin B12 status and change in nerve conduction in response to supplementation1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Adjusted for baseline measure of the neurologic outcome, baseline age, baseline sex and change in skin temperature (foot), unless otherwise stated. 
2 Three subjects with 0 values for tibial CMAP amplitude at baseline or follow-up excluded. 
3Five subjects with 0 values for common peroneal CMAP amplitude at baseline or follow-up excluded. 
4 Four subjects with 0 values for common peroneal CMAP amplitude at baseline or follow-up excluded. 
Change in outcome  Baseline B12 (pmol/L) Baseline holoTC (pmol/L) Baseline tHcy (µmol/L) Baseline cB12 
Motor tibial CMAP 
amplitude (mV) 
n 732 702 722 702 
Β -0.00 (-0.01 - 0.00) 0.01 (-0.01 – 0.03) 0.04 (-0.03 – 0.15) -0.12 (-1.21 – 1.01) 
p 0.45 0.42 0.32 0.84 
Motor common peroneal 
CMAP amplitude (mV) 
n 713 694 703 694 
Β -0.01 (-0.01 - -0.00) 0.00 (-0.01 – 0.01) -0.00 (-0.06 – 0.08) -0.02 (-0.81 – 0.83) 
p 0.02 0.94 0.97 0.97 
Motor tibial conduction 
velocity (m/s) 
n 72 69 71 69 
Β -0.02  (-0.04- -0.01) -0.02 (-0.06 – 0.03) 0.11 (-0.09 – 0.27) -2.12 (-4.40 – 0.34) 
p 0.01 0.40 0.21 0.08 
Motor common peroneal 
conduction velocity (m/s) 
n 71 69 70 69 
Β 0.00 (-0.01 – 0.02) 0.04 (0.00 – 0.09) -0.11 (-0.25 – 0.14) 2.05 (-0.28 – 4.21) 
p 0.75 0.04 0.25 0.07  
Sensory sural SAP 
amplitude (µV) 
n 595 586 597 586 
Β -0.01 (-0.04 – 0.00) -0.01 (-0.04 – 0.03) 0.09 (-0.04 – 0.21) -1.03 (-3.09- 0.59) 
p 0.23 0.64 0.15 0.27 
Sensory superficial 
peroneal SAP amplitude 
(µV) 
n 498 489 4910 489 
Β -0.00 (-0.01 – 0.02) -0.00 (-0.07 – 0.03) 0.07 (-0.26 – 0.37) -0.81 (-4.50 – 1.84) 
p 0.85 0.85 0.66 0.61 
Sensory sural conduction 
velocity (m/s) 
n 59 58 59 58 
Β 0.02 (0.00 – 0.03) 0.03 (-0.02 – 0.07) 0.03 (-0.16 – 0.30) 1.81 (-0.96 – 4.35) 
p 0.05 0.18 0.82 0.17 
Sensory superficial 
peroneal conduction 
velocity (m/s) 
n 49 48 49 48 
Β -0.00 (-0.03 – 0.03) -0.02 (-0.11 – 0.07) 0.17 (-0.15 – 0.62) -1.58 (-7.07 – 3.25) 
p 0.83 0.62 0.38 0.54 
ADM CMCT (ms) n 72 69 71 69 
Β 0.00 (-0.00 – 0.01)11 0.01 (-0.01 – 0.03)11 -0.00 (-0.08 – 0.09)11 0.53 (-0.75 – 1.43)11 
p 0.7711 0.2111 0.9811 0.3111 
AH CMCT (ms) n 66 63 65 63 
Β 0.00 (-0.01 – 0.02) 0.03 (-0.01 – 0.06) -0.07 (-0.20 – 0.08) 2.19 (0.10 – 4.04) 
p 0.77 0.12 0.35 0.03 
Mean abductor digiti 
motor (ADM) MEP 
amplitude (mV) 
n 74 71 73 71 
Β 0.00 (-0.00 – 0.01)11 0.00 (-0.01 – 0.01)11 -0.07 (-0.13 - -0.03)11 0.72 (0.04 – 1.29)11 
P 0.1711 0.3311 0.0011 0.0311 
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5 Seventeen subjects with 0 values for sural SAP amplitude at baseline or follow-up excluded; 8 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP 
amplitude at follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
6 Fifteen subjects with 0 values for sural SAP amplitude at baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude 
at follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
7 Sixteen subjects with 0 values for sural SAP amplitude at baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude 
at follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
8Twenty-seven subjects with 0 values for superficial peroneal SAP amplitude at baseline or follow-up excluded;  11 of these had detectable superficial peroneal SAP amplitude at baseline and 
no detectable (0) superficial peroneal SAP amplitude at follow-up; and 10 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
9Twenty-five subjects with 0 values for superficial peroneal SAP amplitude at baseline or follow-up excluded; 10 of these had detectable superficial peroneal SAP amplitude at baseline and no 
detectable (0) superficial peroneal SAP amplitude at follow-up; and 9 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
10Twenty-six subjects with 0 values for superficial peroneal SAP amplitude at baseline or follow-up excluded; 10 of these had detectable superficial peroneal SAP amplitude at baseline and no 
detectable (0) superficial peroneal SAP amplitude at follow-up; and 10 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
11 Adjusted for baseline measure of the neurologic outcome, baseline age, baseline sex and change in skin temperature (hand). 
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Table 3: Linear regression analyses to assess relationship between change in vitamin B12 status and change in nerve conduction in response to supplementation1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Adjusted for baseline measure of neurologic outcome, baseline B12/holoTC/tHcy/cB12 status, baseline age, baseline sex and change in skin temperature (foot) unless otherwise stated. 
2 Three subjects with 0 values for tibial CMAP at baseline or follow-up excluded. 
3Five subjects with 0 values for common peroneal CMAP at baseline or follow-up excluded. 
Change in outcome  Change in B12 Change in holoTC Change in tHcy Change in cB12 
Motor tibial CMAP 
amplitude (mV) 
n 712 682 702 682 
β 0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.01) -0.07 (-0.22 – 0.08) 0.71 (-0.36 – 1.91) 
p 0.41 0.38 0.34 0.22 
Motor common peroneal 
CMAP amplitude (mV) 
n 693 674 683 674 
β 0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.00) 0.10 (-0.12 – 0.34) 0.52 (-0.14 – 1.39) 
p 0.98 0.31 0.41 0.18 
Motor tibial conduction 
velocity (m/s) 
n 70 67 69 67 
β 0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.01) -0.07 (-0.59 – 0.43) 0.72 (-1.50 – 3.35) 
p 0.98 0.52 0.77 0.57 
Motor common peroneal 
conduction velocity (m/s) 
n 69 67 68 67 
β -0.00 (-0.00 – 0.00) -0.00 (-0.01 – 0.00) 0.10 (-0.39 – 0.78) 0.24 (-1.70 – 2.46) 
p 0.81 0.35 0.75 0.82 
Sensory sural SAP 
amplitude (µV) 
n 585 576 587 576 
β -0.00 (-0.00 – 0.00) 0.00 (-0.01 – 0.01) -0.13 (-0.56 – 0.22) 0.23 (-1.62 – 2.59) 
p 0.93 0.98 0.51 0.82 
Sensory superficial 
peroneal SAP amplitude 
(µV) 
n 498 489 4910 489 
β 0.00 (-0.00 – 0.01) 0.00 (-0.01 – 0.02) -0.37 (-1.08 - -0.00) 2.45 (-0.52 – 7.40) 
p 0.66 0.69 0.15 0.19 
Sensory sural conduction 
velocity (m/s) 
n 58 57 58 57 
β 0.00 (-0.00 – 0.01) 0.00 (-0.01 – 0.01) 0.29 (-0.21 – 0.82) 0.94 (-2.43 – 3.23) 
p 0.05 0.64 0.25 0.51 
Sensory superficial 
peroneal conduction 
velocity (m/s) 
n 49 48 49 48 
β -0.01 (-0.02 – 0.01) -0.01 (-0.03 – 0.01) -0.18 (-0.82 – 0.74) -1.64 (-7.42 – 3.01) 
p 0.37 0.32 0.65 0.54 
ADM CMCT (ms) n 70 67 69 67 
β -0.00 (-0.00 - 0.00)11 -0.00 (-0.00 - 0.00)11 0.02 (-0.19 – 0.17)11 -0.19 (-1.01 – 0.90)11 
p 0.1511 0.3511 0.8111 0.6811 
AH CMCT (ms) n 64 61 63 61 
β 0.00 (-0.00 - 0.00) 0.00 (-0.01 – 0.01) 0.18 (-0.22 – 0.66) 0.42 (-1.53 – 2.02) 
p 0.41 0.84 0.42 0.64 
Mean abductor digiti 
motor (ADM) MEP 
amplitude (mV) 
n 72 69 71 69 
β 0.00 (-0.00 - 0.00)11 0.00 (-0.00 - 0.00)11 -0.03 (-0.13 – 0.07)11 0.50 (-0.27 – 1.23)11 
p 0.3611 0.7211 0.5211 0.1911 
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4Four subjects with 0 values for common peroneal CMAP at baseline or follow-up excluded. 
5Sixteen subjects with 0 values for sural SAP at baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-
up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
6 Fourteen subjects with 0 values for sural SAP at baseline or follow-up excluded; 6 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at 
follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
7Fifteen subjects with 0 values for sural SAP at baseline or follow-up excluded; 6 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-
up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
8Twenty-five subjects with 0 values for superficial peroneal SAP at baseline or follow-up excluded; 10 of these had detectable superficial peroneal SAP amplitude at baseline and no detectable 
(0) superficial peroneal SAP amplitude at follow-up; and 9 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP amplitude at 
follow-up. 
9Twenty-three subjects with 0 values for superficial peroneal SAP at baseline or follow-up excluded; 9 of these had detectable superficial peroneal SAP amplitude at baseline and no 
detectable (0) superficial peroneal SAP amplitude at follow-up; and 8 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
10Twenty-four subjects with 0 values for superficial peroneal SAP at baseline or follow-up excluded; 9 of these had detectable superficial peroneal SAP amplitude at baseline and no detectable 
(0) superficial peroneal SAP amplitude at follow-up; and 9 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP amplitude at 
follow-up. 
11Adjusted for baseline measure of neurologic outcome, baseline B12/holoTC/tHcy/cB12 status, baseline age, baseline sex and change in skin temperature (hand). 
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Figure 1: Vitamin B12 status by quartile of serum vitamin B121, holotranscobalamin2, homocysteine3 and a composite indicator (cB12) in the 
study population (n=91) of older people in the intervention arm of the OPEN study at baseline (0 months) and follow-up (12 months) 
 
1Microbiologic assay 
2Axis-Shield radioimmunoassay 
3Abbott IMx analyzer; Abbott Laboratories 
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